Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Abeona Therapeutics Inc. (ABEO : NSDQ)

• Company Description    Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $5.85 Daily Weekly Monthly 20 Day Moving Average: 1,056,928 shares Shares Outstanding: 51.16 (millions) Market Capitalization: $299.27 (millions) Beta: 1.51 52 Week High: $7.32 52 Week Low: $3.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.33% -9.83% 12 Week 20.87% 1.67% Year To Date 5.03% -1.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6555 Carnegie Avenue 4thFloor - Cleveland,OH 44103 USA ph: 646-813-4701 fax: 214-905-5101 ir@abeonatherapeutics.com http://www.abeonatherapeutics.com

• General Corporate Information    Officers Vishwas Seshadri - Chief Executive Officer; President and Director Michael Amoroso - Chairman of the Board and Director Joseph Vazzano - Chief Financial Officer Leila Alland - Director Mark J. Alvino - Director Peer Information Abeona Therapeutics Inc. (CORR.) Abeona Therapeutics Inc. (RSPI) Abeona Therapeutics Inc. (CGXP) Abeona Therapeutics Inc. (BGEN) Abeona Therapeutics Inc. (GTBP) Abeona Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00289Y206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 51.16 Most Recent Split Date: 7.00 (0.04:1) Beta: 1.51 Market Capitalization: $299.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 54.72% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -118.82 12/31/24 - -163.41 ROA 06/30/25 - - 03/31/25 - -52.48 12/31/24 - -57.47 Current Ratio 06/30/25 - - 03/31/25 - 4.90 12/31/24 - 6.08 Quick Ratio 06/30/25 - - 03/31/25 - 4.90 12/31/24 - 6.08 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.85 12/31/24 - 1.01 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.27 12/31/24 - 0.30 Debt-to-Capital 06/30/25 - - 03/31/25 - 21.20 12/31/24 - 22.84

Powered by Zacks Investment Research ©